期刊文献+

替罗非班对PCI治疗的AMI患者血浆GDF-15及血清PAF的影响 被引量:15

Influence of tirofiban on plasma GDF-15 and serum PAF level in AMI patients undergoing PCI
下载PDF
导出
摘要 目的:探讨替罗非班对接受经皮冠状动脉介入治疗(PCI)的急性心肌梗死(AMI)患者血浆生长分化因子-15(GDF-15)及血清血小板活化因子(PAF)水平的影响。方法:选择2015年1月至2016年12月110例行急诊PCI治疗的AMI患者。根据随机数字表法,患者被随机均分为常规治疗组(接受双联抗血小板等治疗)与替罗非班组(在常规治疗组基础上加用替罗非班)。比较两组患者PCI术后TIMI血流分级、心功能、治疗前后血浆GDF-15及血清PAF水平及不良事件的发生率。结果:与常规治疗组比较,替罗非班组术后7d血清PAF[(10.2±1.7)μg/L比(8.3±1.4)μg/L]、血浆GDF-15[(2.6±0.8)μg/L比(1.5±0.6)μg/L]水平显著降低(P均=0.001)。与常规治疗组比较,替罗非班组术后6个月左室射血分数[(52.8±6.6)%比(57.5±7.3)%]显著升高,而左室收缩末期内径[(45.4±7.1)mm比(40.2±6.9)mm]、左室舒张末期内径[(57.0±7.2)mm比(52.4±7.6)mm]以及不良事件发生率(14.5%比1.8%)显著降低,P<0.05或<0.01。结论:与常规治疗组比较,替罗非班更显著降低PCI术后AMI患者血浆GDF-15、血清PAF水平,改善心功能,且安全性较好,值得推广。 Objective: To explore influence of tirofiban on plasma level of growth differentiation factor-15 (GDF-15) and serum level of platelet activating factor (PAF) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods: A total of 110 AMI patients undergoing emergency PCI from Jan 2015 to Dec 2016 were selected. According to random number table, they were randomly and equally divided in-to routine treatment group (received dual antiplatelet therapy etc. ) and tirofiban group (received tirofiban based on routine treatment group). TIMI blood flow grade and cardiac function after PCI, plasma GDF-15 and serum PAF levels before and after treatment, and incidence of adverse events were compared between two groups. Results: Compared with routine treatment group on 7d after PCI, there were significant reductions in serum PAF level [ (10.2±1.7)μg/Lvs. (8.3±1.4) μg/L] and plasmaGDF-151evel[(2.6±0.8) μg/Lvs. (1.5±0.6) μg/L] in tirofiban group, P = 0. 001 both. Compared with routine treatment group on six months after PCI, there was signifi- cant rise in left ventricular ejection fraction [ (52.8 ± 6.6) % vs. (57.5 ± 7.3) % ], and significant reductions in left ventricular end-systolic dimension [(45.4 ± 7.1) mm vs. (40.2 ± 6.9) mm], left ventricular end-diastolic dimension [ (57.0 ± 7.2) mm vs. (52.4 ± 7.6) mm] and incidence rate of adverse events (14.5% vs. 1.8%) in tirofiban group, P〈0.05 or 〈0.01. Conclusion: Compared with routine treatment , tirofiban can more significantly reduce plasma GDF-15 and serum PAF levels, improve cardiac function in AMI patients after PCI, and it's safe, which is worth extending.
出处 《心血管康复医学杂志》 CAS 2017年第6期651-655,共5页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 血管成形术 气囊 冠状动脉 心肌梗死 替罗非班 Angioplasty, balloon, coronary Myocardial infarction Tirofiban
  • 相关文献

参考文献14

二级参考文献152

  • 1张涛,李自成.冠心病易损斑块的研究进展[J].临床心血管病杂志,2004,20(8):509-512. 被引量:18
  • 2童华诚,郭玉军,李玲,苗晓亮.B型钠尿肽及N端B型钠尿肽原水平与心力衰竭患者心功能的关系[J].检验医学,2006,21(1):58-60. 被引量:19
  • 3曹红翠,杨云梅,黄卫东,徐哲荣.血小板活化因子在急性冠脉综合征患者中的变化[J].中华急诊医学杂志,2006,15(5):451-453. 被引量:8
  • 4Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF -beta superfamily [J]. Proc Natl Acad Sci US A,1997 ,94(21) :11514-11519. 被引量:1
  • 5Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/ reperfusion injury[J]. Circ Res ,2006 ,98 (3) :351-360. 被引量:1
  • 6Johnen H, Kuffner T, Brown DA, et al. Increased expression of the TGF-b superfamily cytokine MIC-lIGDFI5 protects ApoE ( -/ -) mice from the development of atherosclerosis [J]. Cardiovasc Pathol ,2012 ,21 (6) :499-505. 被引量:1
  • 7Yu XH, Jiang HL, Chen WJ, et al. Interleukin-18 and interleukin-12 together downregulate ATP-binding cassette transporter Al expression through the interleukin-18R1 nuclear factor-kappaB signaling pathway in THP-l macrophage-derived foam cells [J]. Circ J, 2012, 76 ( 7 ) : 1780-1791. 被引量:1
  • 8Gu HF, Tang CK, Yang YZ. Psychological stress, immune response, and atherosclerosis [J]. Atherosclerosis, 2012, 223 (1) :69-77. 被引量:1
  • 9Lusis AJ. Atherosclerosis [J ]. Nature, 2000 , 407 ( 6801 ) : 233-241. 被引量:1
  • 10Tan M, Wang Y, Guan K, et al. PTGF -beta, a type beta transforming growth factor (TGF -beta ) superfamily member , is a p53 target gene that inhibits tumor cell growth via TGF -beta signaling pathway [J]. Proc Natl Acad Sci U S A,2000,97(1) :109-114. 被引量:1

共引文献285

同被引文献121

引证文献15

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部